Last updated: August 30, 2026
Accuretic is a fixed-dose combination of quinapril hydrochloride, an angiotensin-converting enzyme inhibitor, and hydrochlorothiazide, a thiazide diuretic. Its commercial opportunity is primarily generic and reformulation-based because the product’s active-ingredient patents and regulatory exclusivities have expired, the therapeutic class is mature, and quinapril products faced nitrosamine-related supply disruption and market withdrawal.
The most defensible product strategy is a low-cost, quality-focused generic with tighter control of nitrite impurities, excipient variability, tablet robustness, and long-term stability. A premium reformulation has limited market potential unless it addresses a defined problem such as lactose exposure, tablet size, swallowing difficulty, or nitrosamine risk.
What is Accuretic and which excipients does it contain?
Accuretic combines quinapril hydrochloride and hydrochlorothiazide in immediate-release tablets. The marketed strengths are 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg, expressed as quinapril hydrochloride/hydrochlorothiazide.[1]
The reference product’s inactive ingredients include the following excipient categories:
| Excipient or category |
Functional role |
Commercial relevance |
| Lactose monohydrate |
Diluent and tablet bulk agent |
Low cost, established compatibility, but excludes lactose-free positioning |
| Magnesium carbonate |
Alkaline stabilizing and bulking component |
Relevant to quinapril stability and microenvironmental pH |
| Gelatin |
Binder or structural excipient |
Creates animal-origin and allergen-screening considerations |
| Crospovidone |
Superdisintegrant |
Supports rapid tablet breakup |
| Povidone |
Binder |
Affects granulation, hardness and dissolution |
| Magnesium stearate |
Lubricant |
Excess use can slow wetting and dissolution |
| Iron oxide |
Colorant |
Supports strength differentiation and product identification |
| Titanium dioxide or related opacifier, depending on presentation |
Opacity and appearance |
May affect global-market acceptability |
| Wax coating components |
Tablet protection and finish |
Relevant to moisture protection and swallowing |
The exact excipient declaration must be confirmed against the applicable FDA-approved labeling and product-specific regulatory records before development or submission. The key formulation issue is not simple ingredient replication. It is demonstrating equivalent dissolution, impurity control, stability and bioequivalence after changing a formulation that contains both a moisture-sensitive ACE inhibitor component and a diuretic.
What excipient strategy is most suitable for a generic Accuretic product?
A conventional immediate-release, direct-compression or low-shear wet-granulation platform is the strongest starting point. The formulation should preserve the reference product’s release profile while reducing avoidable manufacturing complexity.
Strategy 1: Reference-like formulation
A reference-like formulation uses lactose, a binder, a superdisintegrant, a lubricant, an alkaline stabilizer and a colorant. This approach offers the lowest development and regulatory risk because:
- The excipient classes have extensive oral-tablet precedent.
- The product remains close to the reference composition.
- Dissolution development is comparatively predictable.
- Manufacturing can use standard high-speed tablet equipment.
- The formulation is compatible with a conventional ANDA strategy.
The principal weakness is limited differentiation. A reference-like product competes mainly on price, supply reliability and channel access.
Strategy 2: Nitrosamine-control formulation
Nitrosamine control should be central to any current quinapril product strategy. The FDA identified N-nitroso-quinapril contamination in certain quinapril and quinapril/hydrochlorothiazide products and requested recalls of affected lots.[2] FDA guidance treats nitrosamine risk as a lifecycle quality issue involving active ingredients, excipients, water, packaging and manufacturing conditions.[3]
The formulation program should therefore include:
- Nitrite testing for each high-risk excipient lot.
- Supplier qualification that covers nitrosating impurities and process changes.
- Control of amine-containing excipients and their impurity profiles.
- Evaluation of water activity, moisture exposure and storage temperature.
- Packaging studies for bottles, desiccants and high-barrier blisters.
- Stability testing for both N-nitroso-quinapril and conventional degradation products.
- A documented risk assessment under FDA’s nitrosamine guidance.
A supplier-controlled excipient platform could become a commercial differentiator if it supports uninterrupted supply and provides strong quality documentation to pharmacies, wholesalers and institutional buyers.
Strategy 3: Lactose-free formulation
A lactose-free version could replace lactose with microcrystalline cellulose, dibasic calcium phosphate, mannitol or a combination of these materials. This would expand use among patients avoiding lactose and simplify certain global-market registrations.
The main development risks are:
- Different tablet density and size.
- Changed compaction behavior.
- Potential impact on quinapril stability.
- Different dissolution behavior across pH conditions.
- Higher cost for mannitol or specialized grades.
- Possible need for a new bioequivalence formulation rather than a simple manufacturing adjustment.
Lactose-free positioning has commercial value, but the addressable market is narrower than the general generic market. It is more attractive for private-label, hospital and international products than for a broad U.S. retail launch.
Strategy 4: Low-swallowing-burden tablet
Tablet size reduction is possible because the strengths contain only 22.5 mg to 45 mg of active ingredients. A high-density formulation could reduce tablet volume, but it must maintain dose uniformity across the low-dose quinapril/hydrochlorothiazide presentation.
Potential approaches include:
- Higher-density direct compression.
- Roller compaction.
- Film coating with low-weight polymer systems.
- Score-line development where permitted.
- A common tablet platform across all three strengths.
This strategy has practical value for older adults, who represent a major portion of antihypertensive use. It does not create strong patent protection by itself, but it can support a product claim, purchasing preference or private-label agreement.
What formulation patents protect Accuretic?
Accuretic’s principal commercial protection came from old composition and combination-product patents associated with quinapril and hydrochlorothiazide. Those rights have expired or reached the end of their practical exclusivity period. The product does not have a current biologic exclusivity framework, and no biosimilar pathway applies.
| Protection category |
Accuretic status |
Commercial effect |
| Quinapril compound patents |
Expired |
No current compound monopoly |
| Hydrochlorothiazide patents |
Expired |
No current active-ingredient barrier |
| Fixed-dose combination patents |
Expired or commercially spent |
Generic combinations can compete |
| FDA new-drug exclusivity |
Expired |
No remaining regulatory block |
| Formulation patents |
No material current barrier identified in the public product history |
Reformulation must compete on regulatory and commercial execution |
| Method-of-use patents |
No meaningful current barrier for conventional hypertension use |
Limited ability to block generic prescribing |
| Biosimilar exclusivity |
Not applicable |
Product is a small-molecule oral tablet |
An applicant should still conduct a current Orange Book and patent-register review before filing. The relevant risk is unlikely to be a live Accuretic patent. It is more likely to involve formulation-specific patents, manufacturing know-how, impurity-control claims or contractual supply arrangements developed by later entrants.
When did Accuretic lose exclusivity?
Accuretic lost meaningful market exclusivity years before the recent quinapril supply problems. Generic quinapril/hydrochlorothiazide products have been available through the ANDA pathway, and the reference product no longer has a defensible branded pricing moat.
The commercial timeline is more important than a single patent expiration date:
| Period |
Event |
Implication |
| Initial approval era |
FDA approval of quinapril/hydrochlorothiazide fixed-dose therapy |
Established the combination product |
| Patent-expiration period |
Compound and combination rights reached expiry |
ANDA competition became available |
| Mature generic period |
Multiple manufacturers supplied quinapril and hydrochlorothiazide products |
Pricing and supply became the main competitive variables |
| 2022 |
FDA-recognized recalls and market disruption involving N-nitroso-quinapril |
Quality and continuity became strategic concerns |
| Current market |
Brand value is limited and generic replacement is the primary opportunity |
New entrants need a supply or quality advantage |
What is the FDA and Orange Book status of Accuretic?
Accuretic is an approved small-molecule prescription product, but its commercial status has been affected by the discontinuation and recall history of quinapril-containing products. FDA’s Orange Book distinguishes between approved products, discontinued products and products that may remain approved but are not currently marketed. Those categories have different implications for substitution, reference-product selection and ANDA strategy.[4]
A generic sponsor should verify:
- The current reference-listed drug designation.
- Whether the relevant Accuretic product is listed as marketed or discontinued.
- Whether a different quinapril/hydrochlorothiazide product is the applicable reference.
- The availability of FDA-approved generic products.
- Current labeling for nitrosamine warnings and impurity controls.
- Whether any strength has a different regulatory status.
Because the product is a conventional immediate-release tablet, the most likely route is an ANDA rather than a 505(b)(2) application. A 505(b)(2) route would be more relevant for a meaningful new dosage form, altered release profile or clinically differentiated delivery system.
What Paragraph IV challenges and litigation affect Accuretic?
Paragraph IV litigation was commercially relevant when the original quinapril and fixed-dose combination patents remained enforceable. That period has passed. A new generic entrant is more likely to file an ANDA with certifications reflecting expired patents or no current listed patent barrier than to pursue a commercially valuable Paragraph IV challenge.
The key legal risks now are:
- A formulation patent covering a later-developed generic product.
- Patent claims directed to impurity reduction or manufacturing controls.
- Trade-secret restrictions involving a contract manufacturer.
- Regulatory disputes over the appropriate reference product.
- Product-liability exposure associated with nitrosamine contamination.
- Contract disputes concerning discontinued supply or private-label rights.
No biosimilar litigation applies because Accuretic is not a biologic. A new entrant should prioritize freedom-to-operate review around excipient combinations, coating systems, impurity-control processes and packaging rather than the expired quinapril compound.
Which companies are challenging or competing with Accuretic?
The competitive field consists of generic manufacturers and suppliers of therapeutically substitutable antihypertensives. Competition includes:
- Generic quinapril/hydrochlorothiazide manufacturers.
- Generic quinapril suppliers.
- Generic hydrochlorothiazide combinations with other ACE inhibitors.
- ARB/thiazide products such as losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide.
- Single-agent ACE inhibitors and ARBs prescribed as separate tablets.
The strongest commercial substitutes are often not other quinapril combinations. They are lower-cost or better-supplied ARB/thiazide combinations. ARBs have broader contemporary prescribing acceptance and do not carry the same cough-related tolerability issue associated with ACE inhibitors.
What commercial opportunities exist for Accuretic excipient reformulation?
The opportunity is strongest in three segments.
Reliable generic supply
A manufacturer that can demonstrate consistent quinapril impurity control and stable supply can compete for pharmacy, wholesaler and institutional contracts. The product’s recall history creates a commercial opening for a supplier with validated raw-material controls.
Private-label and contract manufacturing
A low-cost tablet platform can support:
- Retail generic distribution.
- Hospital purchasing.
- International licensing.
- Private-label antihypertensive portfolios.
- Combination-product bundles with other cardiovascular medicines.
The commercial value is higher when the manufacturer already has an antihypertensive sales channel. Accuretic alone is unlikely to justify a large standalone sales infrastructure.
Reformulated niche products
A lactose-free, smaller-tablet or high-barrier-packaging product could command modest differentiation. The strongest candidates are:
| Product concept |
Regulatory burden |
Commercial potential |
| Reference-like generic |
Low to moderate |
High-volume, low-margin |
| Nitrosamine-controlled generic |
Moderate |
High if supply reliability is demonstrated |
| Lactose-free tablet |
Moderate |
Moderate, niche |
| Smaller tablet |
Moderate |
Moderate, mainly adherence-driven |
| Orally disintegrating tablet |
High |
Uncertain because of stability and taste challenges |
| Modified-release product |
High |
Low unless supported by clinical differentiation |
| Combination with a different diuretic |
High |
Requires a new development and competitive positioning |
How strong is the Accuretic patent estate?
The Accuretic patent estate is weak as a current exclusivity barrier. Its economic value lies in historical brand recognition, regulatory precedent and formulation know-how, not in enforceable market exclusivity.
A new entrant’s defensibility should come from:
- Controlled nitrite specifications.
- Validated manufacturing processes.
- Stable supply of quinapril hydrochloride.
- Packaging that limits moisture and impurity formation.
- Efficient bioequivalence development.
- Customer contracts and distribution access.
- Potential formulation patents for a genuinely differentiated product.
A patent filing on routine excipient substitution is unlikely to provide durable protection unless it produces an unexpected stability, dissolution or impurity-control result. Trade secrets and quality systems may provide more practical value than narrow formulation claims.
What generic launch risks exist?
The principal launch risks are regulatory, quality-related and commercial.
| Risk |
Probability profile |
Mitigation |
| N-nitroso-quinapril formation |
Material |
Excipient nitrite controls, stability monitoring and supplier audits |
| Limited active-ingredient supply |
Material |
Dual sourcing and qualified alternate suppliers |
| Bioequivalence failure |
Moderate |
Early comparative dissolution and formulation screening |
| Low market price |
High |
Lean manufacturing and contracted distribution |
| Therapeutic substitution by ARB combinations |
High |
Focus on channel-specific demand and supply reliability |
| Discontinued reference-product complications |
Moderate |
Confirm RLD and ANDA pathway before formulation lock |
| Low volume per strength |
Moderate |
Shared manufacturing platform across strengths |
| Packaging-related degradation |
Moderate |
High-barrier packaging and accelerated stability studies |
Key Takeaways
- Accuretic contains quinapril hydrochloride and hydrochlorothiazide in immediate-release tablets.
- Its historic patent and exclusivity barriers are no longer commercially meaningful.
- The best generic opportunity is a reliable, nitrosamine-controlled product with a reference-like formulation.
- Lactose-free and smaller-tablet versions offer niche differentiation but carry higher development costs.
- No biosimilar pathway applies.
- The most important current risks involve N-nitroso-quinapril, active-ingredient supply, reference-product status and competition from ARB/thiazide combinations.
- Patent protection for routine excipient changes is likely to be weak; manufacturing controls, supplier qualification and distribution contracts may provide stronger commercial protection.
- Accuretic is better suited to a portfolio or private-label strategy than to a standalone branded reformulation program.
FAQs About Accuretic Excipient and Commercial Strategy
Can Accuretic be reformulated without a new clinical efficacy trial?
A generic immediate-release reformulation can generally pursue the ANDA pathway if it meets pharmaceutical equivalence and bioequivalence requirements. A materially different dosage form or release profile could require a 505(b)(2) application and additional clinical support.
Is lactose the main excipient opportunity in Accuretic?
Lactose is one of the clearest substitution targets, but it is not necessarily the highest-value target. Nitrite control, alkaline stabilization, tablet compression and moisture protection have greater significance for product quality and recall prevention.
Does Accuretic have biosimilar competition?
No. Accuretic is an oral small-molecule combination product. Competition proceeds through generic drug pathways rather than biosimilar approval.
Could an Accuretic reformulation receive new patent protection?
Possibly, but only a formulation with a technically meaningful and non-obvious result is likely to support strong patent claims. Routine replacement of lactose, magnesium stearate or a colorant would generally provide limited patent strength without unexpected performance data.
Is a quinapril/hydrochlorothiazide product commercially attractive today?
It can be attractive as a low-cost portfolio product or supply-stability play. Its standalone growth potential is limited by mature generic competition, quinapril-related impurity concerns and substitution by ARB/thiazide combinations.
References
- U.S. Food and Drug Administration. (n.d.). Accuretic (quinapril hydrochloride and hydrochlorothiazide) prescribing information.
- U.S. Food and Drug Administration. (2022). FDA updates and press announcements concerning recalls of quinapril and quinapril/hydrochlorothiazide products containing N-nitroso-quinapril.
- U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs: Guidance for industry.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
